Van Hulzen Asset Management LLC Buys Shares of 9,991 LeMaitre Vascular, Inc. $LMAT

Van Hulzen Asset Management LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,991 shares of the medical instruments supplier’s stock, valued at approximately $959,000.

A number of other institutional investors have also made changes to their positions in LMAT. Illinois Municipal Retirement Fund lifted its holdings in shares of LeMaitre Vascular by 1.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 123 shares during the last quarter. NewEdge Advisors LLC increased its holdings in LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares during the last quarter. Federated Hermes Inc. raised its position in LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after purchasing an additional 155 shares during the period. Pictet Asset Management Holding SA raised its position in LeMaitre Vascular by 5.5% in the first quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock valued at $356,000 after purchasing an additional 169 shares during the period. Finally, Sound Income Strategies LLC lifted its stake in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LMAT has been the subject of a number of research reports. Citizens Jmp lifted their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 14th. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $110.60.

LeMaitre Vascular Trading Down 2.3%

NASDAQ:LMAT opened at $79.96 on Tuesday. The firm has a market cap of $1.83 billion, a PE ratio of 28.06, a price-to-earnings-growth ratio of 2.36 and a beta of 0.53. The stock has a fifty day moving average price of $94.14 and a 200 day moving average price of $99.62. LeMaitre Vascular, Inc. has a 12-month low of $78.65 and a 12-month high of $118.01. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). The company had revenue of $70.38 million for the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.LeMaitre Vascular’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 EPS. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.3%. LeMaitre Vascular’s dividend payout ratio (DPR) is 35.09%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.